Biotalys granted patents for Evoca in Europe and the United States

Biotalys, developing protein-based biocontrols for sustainable crop protection, announced that it obtained patents for its first biofungicide, Evoca, from both the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO).

Evoca is a novel protein-based biofungicide that earned an entirely new resistance classification by the Fungicide Resistance Action Committee (FRAC). The product helps control fungal disease in fruits and vegetables. Evoca is currently under review by the U.S. Environmental Protection Agency (EPA) and the Dutch College voor Toelating van Gewasbeschermingsmiddelen en Biociden (CTGB) in the European Union for regulatory approval.

Evoca will pave the way for Evoca NG, which is expected to be Biotalys’ first commercial fungicide from its Agrobody™ technology platform. Evoca and Evoca NG have the same active ingredient which is now protected by the patent grants in Europe and the U.S.

In addition, Biotalys has requested patent protection for the product’s active ingredient in countries around the globe, such as Argentina, Brazil, and South Africa, which are compelling markets for crop protection. The company already obtained various patents worldwide on different elements of its technology and is continuously building its intellectual property protection for its products, formulations and processes.

Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has been listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium.